China Capabilities

Experienced

Relationship

Scientific Soundness
Pioneers of the Chinese Market
Burning Rock is the NGS Market leader in China with a 27% overall market share. We received the first-ever NMPA approved CDx NGS oncology panel in 2018 and the project received the first ctDNA approval as well as the first TMB panel approval.
China’s commercial and regulatory environment has proven to be one of the most difficult regions in the world. We are seeing that the Chinese precision oncology market is growing exponentially and is projected to reach 40 B by 2030.
There is much confusion on the best strategy and best practices of how to commercialize a precision oncology therapeutic, how to run clinical trials, and assay reimbursement as well as legality.
It is also extremely difficult to get the required data, results, reports from patients in China, and Biosample export restrictions are extremely stringent.
Overall Coverage Network


600+
Cumulative Number of Referring Hospitals

350+

28%
In Hospital Channel


600+

80%
We Can Help With
Let Us Be Your Launchpad Into China
Burning Rock has a history of firsts in China and we are the NGS market leader

First IVD NGS
NGS Panel (2018)

First Co-Development of CDx and Drug

First Projected ctDNA & TMB Approval
approval in China as well as the
first projected approval for TMB
(IO Biomarkers)